Literature DB >> 17040330

Psychiatric comorbidity of migraine.

Sandra W Hamelsky1, Richard B Lipton.   

Abstract

Migraine affects nearly 12% of the adult population in the United States and causes significant lost productivity and decrements in health-related quality of life. The burden of migraine and the challenge in managing it are increased by the comorbid psychiatric conditions that occur in association with it. Studies in both clinical and community-based settings have demonstrated an association between migraine and a number of specific psychiatric disorders. This review will focus on the relationships between migraine and depression, generalized anxiety disorder, panic disorder, and bipolar disorder. In large scale population-based studies, persons with migraine are from 2.2 to 4.0 times more likely to have depression. In longitudinal studies, the evidence supports a bidirectional relationship between migraine and depression, with each disorder increasing the risk of the other disorder. Migraine is also comorbid with generalized anxiety disorder (Odds Ratio [OR] 3.5 to 5.3), panic disorder (OR 3.7), and bipolar disorder (OR 2.9 to 7.3). A diagnosis of migraine should lead to a heightened level of diagnostic suspicion for these comorbid psychiatric disorders. Similarly, a diagnosis of one of these psychiatric disorders should increase vigilance for migraine. Treatment plans for migraine should be mindful of the comorbid conditions.

Entities:  

Mesh:

Year:  2006        PMID: 17040330     DOI: 10.1111/j.1526-4610.2006.00576.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  85 in total

1.  Obsessive-compulsive aspects as predictors of poor response to treatments in patients with chronic migraine and medication overuse.

Authors:  M Curone; D D'Amico; G Bussone
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

2.  One-day behavioral treatment for patients with comorbid depression and migraine: a pilot study.

Authors:  Lilian Dindo; Ana Recober; James N Marchman; Carolyn Turvey; Michael W O'Hara
Journal:  Behav Res Ther       Date:  2012-05-27

3.  The relation of PTSD symptoms to migraine and headache-related disability among substance dependent inpatients.

Authors:  Michael J McDermott; Joshua C Fulwiler; Todd A Smitherman; Kim L Gratz; Kevin M Connolly; Matthew T Tull
Journal:  J Behav Med       Date:  2015-11-26

4.  Depression in epilepsy: mechanisms and therapeutic approach.

Authors:  Marco Mula; Bettina Schmitz
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

5.  Treatment of migraine and the role of psychiatric medications.

Authors:  Elisa Cascade; Amir H Kalali; Todd A Smitherman
Journal:  Psychiatry (Edgmont)       Date:  2008-10

6.  Academic aptitude as a predictor of headache proneness during college: could headache be an outcome of low test scores?

Authors:  Christine A Hovanitz; Dawn Lindsay Thatcher
Journal:  Int J Behav Med       Date:  2012-03

7.  A visual migraine aura locus maps to 9q21-q22.

Authors:  P Tikka-Kleemola; V Artto; S Vepsäläinen; E M Sobel; S Räty; M A Kaunisto; V Anttila; E Hämäläinen; M-L Sumelahti; M Ilmavirta; M Färkkilä; M Kallela; A Palotie; M Wessman
Journal:  Neurology       Date:  2010-04-13       Impact factor: 9.910

8.  Predictors of Prolonged Hospital Stay in Status Migrainosus.

Authors:  S Y Modi; D Dharaiya; A M Katramados; P Mitsias
Journal:  Neurohospitalist       Date:  2016-04-05

9.  New uses of the Migraine Screen Questionnaire (MS-Q): validation in the Primary Care setting and ability to detect hidden migraine. MS-Q in Primary Care.

Authors:  Miguel J Láinez; Jesús Castillo; Manuel Domínguez; Gemma Palacios; Silvia Díaz; Javier Rejas
Journal:  BMC Neurol       Date:  2010-06-08       Impact factor: 2.474

10.  Evidence of persistent central sensitization in chronic headaches: a multi-method study.

Authors:  Elena Filatova; Nina Latysheva; Alexey Kurenkov
Journal:  J Headache Pain       Date:  2008-08-09       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.